Adverse outcome pathway-based analysis of liver steatosis in vitro using human liver cell lines
STAR Protocols · 2023-09 · 4 (3) · 102500
DOI: 10.1016/j.xpro.2023.102500 ↗Kurz gefasst
Fachartikel in der Zeitschrift STAR Protocols, 2023-09. Verfasst von Mawien Karaca und 8 weiteren Autor:innen. Beteiligte Einrichtung: German Federal Institute for Risk Assessment, Department of Pesticides Safety, Max-Dohrn-Straße 8-10, 10589 Berlin, Germany. Hauptthemen laut MEDLINE: Adverse Outcome Pathways, Fatty Liver, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Here, we present an in vitro test battery to analyze chemicals for their potential to induce liver triglyceride accumulation, a hallmark of liver steatosis. We describe steps for using HepG2 and HepaRG human hepatoma cells in conjunction with a combination of several in vitro assays covering the different molecular initiating events and key events of the respective adverse outcome pathway. This protocol is suitable for assessing single substance effects as well as mixtures allowing their classification as steatotic or non-steatotic. For complete details on the use and execution of this protocol, please refer to Luckert et al. (2018),1 Lichtenstein et al. (2020),2 and Knebel et al. (2019).3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- German Federal Institute for Risk Assessment, Department of Pesticides Safety, Max-Dohrn-Straße 8-10, 10589 Berlin, Germany.
- German Federal Institute for Risk Assessment, Department Food Safety, Max-Dohrn-Straße 8-10, 10589 Berlin, Germany.
- German Federal Institute for Risk Assessment, Department of Pesticides Safety, Max-Dohrn-Straße 8-10, 10589 Berlin, Germany; Technical University of Berlin, Institute for Chemistry, Straße des 17. Juni 115, 10623 Berlin…
Zitieren
APA
Karaca, M., Fritsche, K., Lichtenstein, D., Vural, Ö., Kreuzer, K., Alarcan, J., Braeuning, A., Marx-Stoelting, P., & Tralau, T. (2023). Adverse outcome pathway-based analysis of liver steatosis in vitro using human liver cell lines. STAR Protocols, 4(3), 102500. https://doi.org/10.1016/j.xpro.2023.102500
Vancouver
Karaca M, Fritsche K, Lichtenstein D, Vural Ö, Kreuzer K, Alarcan J, et al. Adverse outcome pathway-based analysis of liver steatosis in vitro using human liver cell lines. STAR Protocols. 2023;4(3):102500. doi:10.1016/j.xpro.2023.102500
BibTeX
@article{Karaca2023,
author = {Karaca, Mawien and Fritsche, Kristin and Lichtenstein, Dajana and Vural, Özlem and Kreuzer, Katrin and Alarcan, Jimmy and Braeuning, Albert and Marx-Stoelting, Philip and Tralau, Tewes},
title = {Adverse outcome pathway-based analysis of liver steatosis in vitro using human liver cell lines},
journal = {STAR Protocols},
year = {2023},
volume = {4},
number = {3},
pages = {102500},
doi = {10.1016/j.xpro.2023.102500}
}
EUVIMED